Abstracts tagged "Lung Disease and rheumatoid arthritis (RA)"

Abstract Number: 2552 • 2016 ACR/ARHP Annual Meeting
Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
Takuya Matsumoto¹, Toshihisa Kojima¹, Nobunori Takahashi¹, Shuji Asai¹, Nobuyuki Asai¹, Tatsuo Watanabe², Tomonori Kobayakawa³, Naoki Ishiguro⁴, Shingo Iwano⁵ and Satoru Ito⁶, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopeadic Sugery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁵Department of Radiology, Nagoya University Hospital, Nagoya, Japan, ⁶Department of Respiratory Medicine, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological therapy brought an important advance in the treatment strategy for rheumatoid arthritis (RA). However, the safety of biological therapy on RA patients with…
Abstract Number: 32 • 2015 ACR/ARHP Annual Meeting
Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study
Katerina Chatzidionysiou¹, Gudrun Reynisdottir², Vijay Joshua², Thomas Frisell³, Johan Askling³ and Anca I Catrina², ¹Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: It has been shown that patients with Rheumatoid Arthritis (RA) are at increased risk for certain malignancies, among them lung cancer. We aimed to…
Abstract Number: 1600 • 2015 ACR/ARHP Annual Meeting
Pulmonary Manifestations in Early Rheumatoid Arthritis: A 6 Month Follow up Study
Gudrun Reynisdottir¹, Helga Olsen², Johan Grunewald², Magnus Skold², Anders Eklund³ and Anca I Catrina⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Pulmonary manifestations are common in rheumatoid arthritis (RA). However, limited information is available concerning the early development of such manifestations in newly diagnosed patients.…
Abstract Number: 1421 • 2014 ACR/ARHP Annual Meeting
Preclinical Interstitial Lung Disease in Early Rheumatoid Arthritis
Javier Narváez¹, Alejandro Robles Perez², Maria Molina Molina³ and Joan Miquel Nolla⁴, ¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Early detection and treatment of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) may ameliorate disease progression. The objective of the present…
Abstract Number: 2405 • 2013 ACR/ARHP Annual Meeting
Respiratory Diseases As Risk Factors For Rheumatoid Arthritis
Marie Holmqvist¹, Johan Askling¹, Lars Alfredsson², Camilla Bengtsson², Fredrik Nyberg³ and Göran Tornling⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³AstraZeneca R&D, Mölndal, Sweden, ⁴Respiratory Medicine Unit, Department of Medicine Solna and CMM, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The etiology of rheumatoid arthritis (RA) is only partly understood. In addition to smoking, other airway exposures, e.g. silica dust and traffic pollution, have…
Abstract Number: 1325 • 2013 ACR/ARHP Annual Meeting
A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada Del Rincon², Roy W. Haas³, Daniel F. Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Medicine / MCHE-MDR, San Antonio Military Medical Center, San Antonio, TX, ⁵Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
A Novel Index to Identify Interstitial Lung Disease in Rheumatoid Arthritis Patients José Félix Restrepo1, Inmaculada del Rincón1, Roy W Haas1, Daniel F Battafarano2, Agustín Escalante1…
Abstract Number: 409 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lung Inflammation Evaluated With High Resolution Computed Tomography Scan Is Correlated To Rheumatoid Arthritis Disease Activity
Jorge Rojas-Serrano¹, Renzo Perez-Dorame², Heidegger Mateos-Toledo² and Mayra Mejia³, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Interstitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosío Villegas. México DF., México, D.F., Mexico
Background/Purpose: To describe the association between rheumatoid arthritis disease activity (RA) and interstitial lung damage (inflammation and fibrosis), in a cohort of rheumatoid arthritis-associated interstitial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].